With 2026 now in full swing, it’s time to announce the global podium for robotics — brought to you by the ROBO Global Robotics and Automation Index (ROBO).

Artificial intelligence has brought about a paradigm shift in the diagnostics industry, enhancing the accuracy, speed, and efficiency of disease detection. AI can now process and analyze vast, complex datasets, from medical images and lab reports to genetic data, far beyond human capacity.

Investors who watched the robotics space peak back in 2021 may see the current rally with apprehension. Back then, the narrative of a China-driven logistics and e-commerce boom sent robotics stocks to dizzying heights. What followed was China’s economy first slowing down, and then a pandemic-fueled demand shock. The sector fell hard.

Join Zeno Mercer and Rafael Silva for an investor-focused exploration of three interconnected systems shaping the future of health: artificial intelligence, the human body, and the robotic body.

In 2006, Andrew Fire and Craig Mello shared the Nobel Prize in Physiology or Medicine for their discovery of RNA interference (RNAi), which they published in 1998. Since then, the potential of a technology capable of silencing disease-causing genes has been a very attractive proposition.

Artificial intelligence is poised to revolutionize healthcare. Its headline-grabbing potential in drug discovery is still years from materializing. However, its impact is already tangible in diagnostics and treatment selection. Leading this immediate charge is Tempus AI, a company focused on structuring the complex data needed to make personalized patient care a reality.

Investing in healthcare has long been a cornerstone of defensive, long-term growth strategies. It is, after all, a massive and expanding segment of the global economy.

The healthcare industry's bellwether event, the JP Morgan Healthcare Conference (JPM25), kicked off the year as it traditionally does,